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Abstract
Purpose: This study investigated ocular surface components that contribute to matrix-metalloproteinase (MMP)-2 and
MMP-9 found in tears following corneal epithelial wounding.
Methods: Laboratory short-haired cats underwent corneal epithelial debridement in one randomly chosen eye (n = 18). Eyeflush tears were collected at baseline and during various healing stages. Procedural control eyes (identical experimental
protocol as wounded eyes except for wounding, n = 5) served as controls for tear analysis. MMP activity was analyzed in
tears using gelatin zymography. MMP staining patterns were evaluated in ocular tissues using immunohistochemistry and
used to determine MMP expression sites responsible for tear-derived MMPs.
Results: The proMMP-2 and proMMP-9 activity in tears was highest in wounded and procedural control eyes during
epithelial migration (8 to 36 hours post-wounding). Wounded eyes showed significantly higher proMMP-9 in tears only
during and after epithelial restratification (day 3 to 4 and day 7 to 28 post-wounding, respectively) as compared to
procedural controls (p,0.05). Tears from wounded and procedural control eyes showed no statistical differences for proMMP-2 and MMP-9 (p.0.05). Immunohistochemistry showed increased MMP-2 and MMP-9 expression in the cornea during
epithelial migration and wound closure. The conjunctival epithelium exhibited highest levels of both MMPs during wound
closure, while MMP-9 expression was reduced in conjunctival goblet cells during corneal epithelial migration followed by
complete absence of the cells during wound closure. The immunostaining for both MMPs was elevated in the lacrimal gland
during corneal healing, with little/no change in the meibomian glands. Conjunctival-associated lymphoid tissue (CALT)
showed weak MMP-2 and intense MMP-9 staining.
Conclusions: Following wounding, migrating corneal epithelium contributed little to the observed MMP levels in tears. The
major sources assessed in the present study for tear-derived MMP-2 and MMP-9 following corneal wounding are the
lacrimal gland and CALT. Other sources included stromal keratocytes and conjunctiva with goblet cells.
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[4–6] and ocular surface conditions such as dry eye [7–9],
meibomian gland dysfunction and keratoconjunctivitis sicca
[9,10], as well as systemic conditions including diabetes [11] and
breast cancer [12].
Matrix-metalloproteinases (MMPs), specifically MMP-2 (gelatinase A) and MMP-9 (gelatinase B), are in tears and also in corneal
tissue during wound healing and in ocular surface disease,
including dry eye and keratoconus [4,13–18]. MMPs are key
effectors and regulators of inflammation, wound healing, tissue
remodeling and pathogenic processes [19,20]. Most MMPs are
secreted in an enzymatically inactive state, as pro-enzymes, which
are activated in a proteolytic manner by direct cleavage of the pro-

Introduction
The ocular surface is a complex unit comprised of various
epithelial and glandular tissues (cornea, bulbar and palpebral
conjunctiva, lacrimal glands and accessory eyelid glands) that
secrete essential tear film components. These tissues are connected
by a continuous epithelium as well as the nervous, immune and
endocrine systems [1,2].
The ocular surface system is bathed by the extracellular tear
film which reflects ocular and systemic health. Tears can be
collected using absorbent filter paper, sponges or glass microcapillary tubes [3]. Changes in the protein composition of
collected tears have been associated with ocular wound healing
PLOS ONE | www.plosone.org

1

August 2013 | Volume 8 | Issue 8 | e71948

MMP-2 and MMP-9 in the Ocular Surface

peptide by another MMP or a non-proteolytic manner by
organomercurials.
It is well understood that each of the ocular surface tissues
contribute to the tear film makeup, thus it is more appropriate to
consider the entire ocular surface microenvironment when
analyzing tear proteins present during wound healing or in disease
conditions [1]. However, for both anatomical and ethical reasons,
tissue samples are not routinely collected from patients in clinical
research. Hence, there has been no thorough investigation of
which ocular surface tissues secrete MMP-2 and/or MMP-9 into
the tear film during corneal wound healing. The current study
aimed to address this issue by identifying ocular surface tissues that
contribute to the MMP levels detected in tears following a corneal
epithelial debridement in a feline model.

wire lid speculum and rinsed with sterile saline. The globe was
maintained in a central position using forceps.
A central corneal epithelial debridement 9 mm in diameter was
created in the experimental eye of each animal by the same
surgeon (AP) according to a surgical procedure previously reported
[26]. Prior to performing this debridement procedure on cats, the
surgeon practiced corneal epithelial debridement on bovine eyes
sourced fresh from the local abattoir checking each debridement
by routine histology to ensure the corneal epithelium was
completely removed without disruption to the basement membrane or anterior stroma. After surgery, the animal was placed on
a warming blanket and Hartman’s Solution (Compound sodium
lactate intravenous infusion BP; Baxter Healthcare, Sydney,
Australia) was administered subcutaneously. Eight hours after
wounding, the analgesic buprenorphine hydrochloride (0.005–
0.01 mg/kg) was given subcutaneously to alleviate any discomfort
or pain to the animal.
Procedural control animals served as controls for the analysis of
tears. These procedural control animals were not wounded, but
received identical medications and experimental procedures as the
wounded animals, including general anesthesia, topical eye drops,
eyelid retraction, positioning of the eyeball using forceps and postoperative medications. Eye-flush tears were collected from both
wounded and procedural control eyes after instillation of 10 ml of
sterile saline and immediately placed on ice [26,31]. Tear samples
were stored at 280uC until analysis. Tears were collected at the
baseline prior wounding and at various time points post-wounding
(8, 16, 24 and 36 hours post-wounding; 48 hours post-wounding
and wound closure; 3, 4, 5, 6, 7, 10, 14, 18, 21, 26 and 28 days
post-wounding). Individual tear samples were analyzed each for
the total protein content and MMP-2 and MMP-9 activity (see
tear analysis). One to three animals were sacrificed with an
overdose of sodium pentobarbital (Virbac Australia Pty, Sydney,
Australia) at each predetermined time point (prior to wounding; 8,
16 and 24 hours post-wounding, 48 hours and wound closure; 7,
14 and 28 days post-wounding). Ocular surface tissues, specifically
the corneas, conjunctivas, lacrimal glands and eyelids, were
collected at each time point and fixed in 4% neutral buffered
formalin, paraffin embedded and prepared for MMP-2 and MMP9 expression (see tissue analysis).
The time points were categorized as different healing phases by
daily slit lamp and post-mortem histology examination of each
wounded eye. These phases are listed in Table 1 and are as
follows: 1) prior to wounding (as tissue controls); 2) following
wounding, during early reepithelisation (at 8 and 16 hours postwounding); 3) late epithelial migration (at 24 and 36 hours postwounding); 4) wound closure (43 to 50 hours post-wounding); 5)
early restratification (at 3 and 4 days post-wounding); 6) late phase
restratification (at 5 and 6 days post-wounding); and 7) following
full restratification (at 7, 14 and 28 days post-wounding). Each of
the analyzed tear samples from wounded and procedural control
eyes were grouped into healing phases as outlined in Table 1 to
enable a statistical comparison between various stages of wound
healing.

Materials and Methods
Animal Model
The feline model has been chosen for the current study as it has
been successfully used for wound healing studies in refractive
surgery [21–23] and following corneal epithelial removal using
heptan-1-ol [24], investigations of corneal sensitivity and nerve
regeneration after non-penetrating keratotomy or penetrating
autografts [25] and analysis of tear proteins following corneal
epithelial debridement [26]. Different to most animal models, the
feline cornea possesses fibrils that resemble a Bowman’s membrane [27,28] and a similar corneal epithelial thickness as a human
[29,30].
Furthermore, analysis of MMP levels following a corneal
epithelial debridement wound in a feline model has been
previously published [26]. Specifically, the study showed that
proMMP-9 levels in feline tears were highest on day 1 and reduced
to lower levels by day 3.

Experimental Animals
Studies were conducted in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research and with approval from the Vision CRC and Brien
Holden Vision Institute Animal Ethics Committee (Permit
number: VIAC 06/04). Twenty-three laboratory adult shorthaired cats (14 males, 13 females; 1.860.9 years; 4.161.1 kg) were
included. Consistent with practice in the host institution,
nictitating membranes were removed (as previously described
[31]) from both eyes of each animal at least 8 weeks prior to
enrolment in the study. At the time of enrolment, no clinical signs
of ocular surface disturbance were observed using a slit lamp.

Experimental Design
Surgical procedures on animals were performed under general
anesthesia: intramuscular injection of ketamine 3 mg/kg body
weight, acepromazine maleate 0.05 mg/kg body weight (Delvet,
Seven Hills, Australia) and atropine sulphate 0.02–0.04 mg/kg
body weight (Apex Laboratories, Somersby, Australia), and 5%
isoflurane vaporized in 2 L oxygen (Veterinary Companies of
Australia, Kings Park, Australia) delivered through an endotracheal tube. Upon anesthesia, the analgesic, buprenorphine
hydrochloride 0.005–0.01 mg/kg (Reckitt Benckiser Healthcare
Limited, Hull, UK), was administered subcutaneously. Eye drops
were administered into the randomly selected eye (hereafter
referred to as the experimental eye) prior to the procedure as
follows: local anaesthetic, 0.4% oxybuprocaine hydrochloride;
ophthalmic antibiotic, 0.3% tobramycin; ophthalmic cycoplegic,
0.5% tropicamide (Bausch & Lomb, Sydney, Australia). The
eyelids of the experimental eye were retracted with a Barraquer
PLOS ONE | www.plosone.org

Tear Analysis
Total protein content from each tear sample was measured
using a Pierce Micro BCA protein assay kit (Rockford, IL)
following the manufacturer instructions. The MMP activity in
tears was determined using gelatin zymography [26]. Briefly, a
total protein content of 5 mg for each individual tear sample, a low
range molecular weight standard (Precision Plus Protein Standard
Kaleidoscope; Bio-Rad, Hercules, CA, USA), a gelatinase
zymogram standard (dilution of 1/2000; Chemicon, Temecula,
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Table 1. Tear sample grouping based on wound healing stages for both wounded and procedural control eyes.

Stages

Morphological characteristics of
wound healing

Pooled time points (postwounding)

No. of samples for
wounded animals

No. of samples for procedural
control animals

1

prior wounding

0

18

5

2

early migration

8 and 16 hours

22

6

3

late migration

24 and 36 hours

16

5

4

wound closure

48 hours and wound closure

11

3

5

early restratification

3 and 4 days

12

4

6

late restratification

5 and 6 days

12

4

7

fully restratified epithelium

7, 10, 14, 18, 21, 25 and 28 days

22

8

doi:10.1371/journal.pone.0071948.t001

with coverslips. Images of sections were captured using a Nikon
Digital Sight DS-5M camera with integrated software (Nikon View
6, Japan) attached to a light microscope (Zeiss Imager A1 AX10,
Germany).

CA, USA), 1 mM 4-aminophenyl-mercuric acetate (APMA)
activated MMP-9 standard (total concentration of 0.04 mg; R&D
Systems) as well as 1 mM APMA activated and non-activated
human fibroblast culture media were loaded into pre-cast 10%
Novex zymography gelatin gels (Invitrogen, Carlsbad, CA).
Separation of proteins was performed by electrophoresis at 125
Volt for 2.5 hours. Gels were rinsed in 1X renaturing buffer
(Invitrogen) and incubated overnight in 1X developing buffer
(Invitrogen) at 37uC for 18 hours. Gels were stained in 0.25%
Coomassie Blue and destained in methanol:glacial acetic acid:distilled water (5:1:4). The clear bands on a blue stained
background indicated gelatin degradation from the presence of
MMP activity. These bands were identified as pro-enzymes (proMMP-2 and pro-MMP-9) and activated MMP (MMP-2 and
MMP-9) forms based on their molecular weight. Gels were
scanned and the images were analyzed using a densitometer (GS800, Bio-Rad, Hercules, CA) and an image analysis program (BioRad Quantity one). Optical density (OD) values of clear bands
were calculated and an automatic volume tool was applied to
count the number of gel pixels in each band, to determine the
volume of the gelatin degradation. OD values and number of gel
pixels were multiplied to quantify MMP activity of each band (OD
* number of gel pixels).

Data Analysis
Differences in MMP activity between tear samples collected
from wounded and procedural control eyes were statistically
analyzed with a linear mixed model using the SPSS package (SPSS
Statistics Gradpack 17.0; Chicago, IL, USA). A log-transformation
was applied to provide variance-stability and normal data
distribution. The statistical significance level was set at p,0.05
and a post-hoc analysis was performed to account for multiple
comparisons.

Results
Tear Analysis
Table 2 displays activity levels of proMMP-2, proMMP-9 and
MMP-9 detected in tears from wounded and procedural control
eyes during each of the investigated healing phases. The statistical
analysis revealed that wounded eyes had significantly increased
proMMP-9, MMP-9 and proMMP-2 activity during early (8 to 16
hours) and late (24 to 36 hours) migration of the corneal
epithelium (p,0.001, Table 2). Procedural control eyes exhibited
an increase of MMP activity during the stage equivalent to early
wound healing, but only proMMP-2 was found to be significantly
elevated in tears collected at 8 to 16 hours and 24 to 36 hours
(p,0.001, Table 2). A comparison between wounded and
procedural control eyes showed that the wounded eyes had a
significantly higher level of proMMP-9 activity during early (3 and
4 days post-wounding) and complete (7 to 28 days post-wounding)
corneal epithelial restratification as compared to procedural
control eyes (p,0.04, Table 2). There were no significant
differences in the levels of pro-MMP-2 and MMP-9 between the
wounded and procedural control group at any time point.
Although not significant, an elevation of pro-MMP-2 levels was
observed in procedural control eyes during equivalent stages of
early (8 and 16 hours post-wounding) and late (24 and 36 hours
post-wounding) migration of the epithelium as compared to
wounded animals (p = 0.078 and p = 0.05 respectively). Outliers
were not removed during the statistical analysis and the higher
proMMP-2 activity noted in procedural control eyes at 8 and 16
hours following the procedure is due to the inclusion of the two
outliers. MMP-2 was not detected in any of the tear samples (data
not shown).

Tissue Analysis
Ocular tissues collected at the different time points were fixed in
4% neutral buffered formalin for 6 hours and then transferred to
70% ethanol until processing to paraffin. Embedded tissue was
routinely sectioned at 4 mm and immunostained as previously
described [31]. Briefly, this involved incubation for 20 minutes in
3% H2O2 solution at room temperature, 1X universal decloaker
buffer (Biocare Medical) for 20 minutes in a water bath at 80uC,
primary antibody (mouse anti-human MMP-2 at 20 mg/ml or
rabbit anti-human MMP-9 at 20 mg/ml detecting both pro- and
activated forms, Thermo Fisher Scientific, Fremont, CA) or neat
universal serum as negative control (Biocare Medical, Concord,
CA) for 1 hour at room temperature. This was followed by
incubation with the secondary antibody (biotin conjugated antimouse or anti-rabbit IgG at 30 mg/ml, Zymed Laboratories,
Invitrogen, Carlsbad, CA) for 30 minutes at room temperature,
streptavidin-HRP (Biocare Medical) for 30 minutes at room
temperature and substrate chromogen solution (DAB chromogen
system; Carpinteria, CA) for 5 minutes at room temperature.
Tissue sections were extensively rinsed with 1x TRIS buffered
saline (Biocare Medical) after each incubation step. Tissue sections
were counterstained with haematoxylin (Fronine Pty Ltd, Sydney,
Australia) and mounted in Ultramount (No.4; Fronine Pty Ltd)
PLOS ONE | www.plosone.org

3

August 2013 | Volume 8 | Issue 8 | e71948

MMP-2 and MMP-9 in the Ocular Surface

PLOS ONE | www.plosone.org

Activity of proMMP-2, proMMP-9 and MMP-9 in tears from wounded and procedural control eyes at different phases of epithelial healing.
1
Optical Density (OD) multiplied by the number of gel pixels.
*significantly greater MMP activity when compared to before wounding/procedure (p,0.001).
{
significantly greater proMMP-9 activity in wounded eyes as compared to procedural control eyes (p,0.04).
doi:10.1371/journal.pone.0071948.t002
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2 (1–9)

2 (1–5)
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The immunoreactivity of MMP-2 and MMP-9 in the corneal,
conjunctival, lacrimal gland and meibomian gland tissues of
wounded and unwounded control eyes are depicted in Figures 1
and 2. Examination of the tissue sections stained with the different
antibodies and visualized with DAB which reveals brown staining
of positive antibody responses, showed little or no detectable
MMP-2 and MMP-9 in the epithelium and stroma of unwounded
corneas (Figures 1A, 1E, 2A and 2E). In wounded corneas,
increased MMP-2 and MMP-9 reactivity was observed at the
epithelial wound edge at 16 hours post-wounding and at wound
closure at 43 hours post-wounding (Figures 1B, 1C, 2B and 2C). At
the time of wound closure, MMP-2 was concentrated to the most
superficial and basal columnar epithelial cells (Figure 1C) while
MMP-9 reactivity was evenly distributed in all epithelial layers
(Figure 2C). Increased MMP-2 and MMP-9 immunostaining were
observed in keratocytes during epithelial migration and wound
closure, with particularly high levels found for MMP-9 expression
(Figures 2F and 2G). After full recovery of the epithelial cell layers
following wounding, expression level and distribution of MMPs in
the corneal epithelium and stroma returned to the low baseline
levels, similar to those seen in the unwounded corneas.
The conjunctival epithelium of unwounded eyes showed weak
MMP-2 immunostaining in all cell layers, while MMP-9 was
predominantly seen in the basal epithelium and conjunctival
goblet cells (Figures 1I and 1I). In wounded eyes during corneal
epithelial migration (Figure 1J and 1K), the conjunctival epithelium showed increased MMP-2 with distinctly higher levels
observed at the time of wound closure as compared to unwounded
eyes. The highest levels of MMP-9 immunoreactivity in the
conjunctival epithelium were observed during wound closure
(Figures 2K). We noted an absence of mucin-producing conjunctival goblet cells in the tissue collected during corneal healing at
the time of wound closure (43 to 50 hours post-wounding). Once
healing was completed and the corneal epithelium restratified
(from day 7 post-wounding onwards), the staining pattern of
MMP-2 and MMP-9 was identical to unwounded eyes with the
exception of slightly reduced MMP-9 reactivity in conjunctival
goblet cells.
The lacrimal glands of unwounded animals showed low
intensity of MMP-2 and MMP-9 immunoreactivity (Figures 1M
and 1M). The expression of both MMPs was increased during
corneal healing with immunoreactivity observed in the entire acini
of the lacrimal glands (Figures 1N, 1O, 2N and 2O). When the
epithelium was fully restratified (day 7 post-wounding onwards),
the lacrimal gland showed similar immunoreactivity of MMP-2
and MMP-9 as seen in unwounded eyes.
MMP-2 expression was similar in meibomian glands of both
unwounded and wounded eyes and was observed mainly in the
basement membrane of acini (Figures 1Q–S). In contrast, MMP-9
was expressed throughout all aspects of the glandular tissue of
unwounded eyes (Figure 2Q) and only very slightly increased in
intensity during corneal epithelial healing (Figures 2R and 2S). In
meibomian glands collected from animals with a fully restratified
corneal epithelium (from day 7 post-wounding onwards), the
immunoreactivity of MMP-9 appeared to be diminished in
comparison to unwounded eyes.
Conjunctival-associated lymphoid tissue (CALT) was detected
beneath the palpebral conjunctiva in the proximity of the fornix of
wounded eyes. Figure 3 presents light micrographs of MMP
immunoreactivity in CALT of the palpebral conjunctiva collected
at the time of wound closure. MMP-2 was mainly found between
the cells comprising CALT (Figure 3A), while MMP-9 showed
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0
Prior to wounding
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proMMP-91
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proMMP-91
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Table 2. MMP-2 and MMP-9 activity in tears.
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Procedural control eyes

MMP-91

proMMP-21

Ocular Surface Immunohistochemistry
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Figure 1. MMP-2 expression in ocular surface tissues. Representative light micrographs of tissue sections showing MMP-2 expression (A–D)
corneal epithelium, (E–H) stromal keratocytes, (I–L) bulbar conjunctival epithelium, (M–P) lacrimal gland and (Q–T) meibomian gland of unwounded
control eyes collected prior to surgery and wounded eyes at various phases of healing. Arrows indicate stromal keratocytes. Arrow head shows an
example of a conjunctival goblet cell.
doi:10.1371/journal.pone.0071948.g001

cells at the tip of the leading edge of the migrating epithelium after
wounding. When the wound had closed, MMP-9 was evenly
distributed in the central epithelial area and returned to the
baseline level following full restratification of the corneal
epithelium (from day 7 post-wounding onwards), consistent with
completion of the wound healing process. MMP-2 was also
detected in corneal epithelial cells at the leading edge of migrating
cells during wound healing. At the time of wound closure, MMP-2
was mainly localized at a still elevated intensity in the most outer
and inner corneal epithelial cell layers and reduced to baseline
levels after full recovery of the corneal epithelium (from day 7 postwounding onwards).
MMP-9 has been recently reported to play an important role in
the disassembling process of hemidesmosomes, the epitheliumbasement membrane cell surface attachment sites in corneal
epithelium [34]. MMP-9 was found to specifically cleave the
membrane protein b4 integrin within the hemidesmosome, which

strong expression within the cell body and the intercellular space
of CALT (Figure 3B).

Discussion
The tear film is an integral part of the ocular surface and
provides an easily accessible source of both qualitative and
quantitative information to assess its health [10]. There is great
interest in using diagnostic tools to detect elevated tear MMP
levels to diagnose dry eye or even poor ocular surface conditions
prior to surgery in an effort to improve post-surgical outcomes
[32,33]. However, it is not fully understood which of the ocular
surface tissues produce the MMPs found in the tear film. The
present study simultaneously explored the expression patterns of
MMP-2 and MMP-9 in tears and ocular surface tissues at various
stages of wound healing following corneal epithelial debridement.We observed that MMP-9 was strongly expressed within the

PLOS ONE | www.plosone.org
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Figure 2. MMP-9 expression in ocular surface tissues. Representative light micrographs of tissue sections showing MMP-9 expression in (A–D)
corneal epithelium, (E–H) stromal keratocytes, (I–L) bulbar conjunctival epithelium, (M–P) lacrimal gland and (Q–T) meibomian gland of unwounded
control eyes collected prior to surgery, and wounded eyes at various stages of healing. Arrows indicate stromal keratocytes. Arrow head shows an
example of a conjunctival goblet cell.
doi:10.1371/journal.pone.0071948.g002

Figure 3. MMP-2 and MMP-9 expression in conjunctival associated lymphoid tissue (CALT) in the palpebral conjunctiva.
Representative light micrographs of a section through CALT showing (A) MMP-2, (B) MMP-9 expression and (C) IgG control, at the time of corneal
wound closure.
doi:10.1371/journal.pone.0071948.g003
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closure, when tear MMP levels were already diminished. This
further suggests that the conjunctival epithelium may have only a
minor contribution towards MMPs detected in the tear film.
Unwounded control eyes showed MMP-9 activity in the goblet
cells of the conjunctiva. To ensure that the immunoreactivity
detected was not the result of omnipresent stickiness of the mucin
secreted by goblet cells, we compared MMP-9 staining to that
found using a lypholized universal control serum reconstituted
with antibody diluent to a concentration of 10 or 20 mg/ml. No
immunoreactivity in goblet cells was observed for the universal
control (Figure 3). During early wound healing, we no longer
observed MMP-9 in the goblet cells, which may indicate that these
cells expelled their contents of mucin and MMP-9 into the tear
film contributing to the increase in tear MMP-9 activity. This is
further supported by the observation that at the time of wound
closure, conjunctival goblet cells appeared to be absent consistent
with lower tear-derived MMP-9 levels. Conjunctival goblet cells
re-appeared in tissue sections, but with a much reduced intensity
of MMP-9, once the corneal epithelium had fully healed. We did
not assess changes in goblet cell numbers in the procedural control
animals, hence we cannot ascertain their full contribution toward
MMP-9 in tears.
In the lacrimal glands from animals with wounded eyes, the
expression of MMP-2 and MMP-9 was elevated during corneal
epithelial migration and at the time of wound closure compared to
the levels in lacrimal tissue from the unwounded eyes. When the
corneal epithelium was fully restratified (from day 7 postwounding onwards), lacrimal glands showed MMP expression
comparable to that found in the lacrimal glands collected from
unwounded animals. At the current time we can find no published
reports on the expression of MMPs in the lacrimal gland following
corneal wounding. However, increased MMP-9 levels have been
associated with inflamed lacrimal glands in a rabbit dry eye model
[39]. In the feline model in our study, inflammatory cells were
present in the lacrimal gland, although experimental procedures
did not directly interfere with the lacrimal gland. Elevated levels of
MMP-9 were noted in both wounded and procedural control
animals. This indicated that some of the experimental procedures
and/or medications caused inflammation in the lacrimal gland
which subsequently induced the acini to produce and secrete
MMP-9. Furthermore, the lacrimal gland has direct access to the
tear film and may hence be a major contributor to tear MMPs.
The eyelid meibomian glands collected from unwounded
animals demonstrated relatively high MMP-2 and MMP-9
productions in the acinar cells. However, the current study
showed little change of MMP immunoreactivity in meibomian
glands after epithelial wounding and, therefore, a contribution of
this glandular tissue towards tear-derived MMPs with wounding
was considered unlikely.
The inner conjunctival lining of the eyelids were also explored
for additional sources capable of producing MMPs following
wounding. We found that CALT was associated with weak MMP2 and strong MMP-9 immunoreactivity. This outcome is
consistent with lymphoid tissue structures in the colon (Peyer’s
patches), which have also been observed to express MMP-9 [40].
As such, CALT, which can easily release proteins into tears due to
its close proximity with the tear film [41,42] may be another major
source of tear MMPs.
A further important contributor towards MMP levels, not
investigated here, may be the polymorphonuclear leukocytes
(neutrophils, PMNs) which store MMP-9 in their granules [43].
PMN cells are closely associated with corneal wound healing and
can be found in both tears and the ocular surface tissue [44].

in turn facilitates the movement of the corneal epithelial sheet
across the basement membrane to close the wound [34].
Therefore it is not unexpected that we observed a high level of
MMP-9 expression in the healing corneal epithelium.
The observed distribution pattern of MMP-2 and MMP-9
during corneal epithelial migration in the present study was similar
to that observed in a mouse debridement model [35]. In contrast
to the present study however, an in vitro study using human corneal
tissue detected only little MMP-9 in the migrating epithelium, with
increased levels of MMP-9 once multiple epithelial layers were
established [36] In the present study we found the highest level of
MMP-9 expression in the leading edge of the healing epithelium,
with its expression reduced at the time of wound closure. The
different outcomes observed between these two studies could be
due to the different tissue species used in the studies (human vs
animal tissues), or, more likely, result from other factors such as the
debridement technique used and/or the in vitro nature of the study
design. In vitro investigations cannot totally mimic wound healing
responses that occur in the eye, because important ocular surface
components, including inflammatory cells and corneal nerves are
not present. These components are essential in contributing to
healing processes and MMP expression in vivo. It is also possible
that MMP expression may be induced during tissue preparation of
the corneas for organ culture, which was demonstrated in organ
cultured rabbit corneas [37]. This finding, if considered alone,
suggests that the corneal epithelial cells produce MMP-2 and
MMP-9 that may be released into the tear film.
In tears, we detected increased activity of MMP-2 and MMP-9
during corneal epithelial migration, which returned to baseline
levels at the time of wound closure. We used tears collected from
procedural control animals (undergoing the identical experimental
protocol as the wounded animals except for the wounding itself) as
experimental controls for tear analysis. These procedural control
eyes, however, showed similar tear MMP-2 and MMP-9 levels as
wounded eyes. This indicated that the actively migrating corneal
epithelium contributes very little to the observed MMP levels in
tears, and other ocular surface tissues must be responsible for the
detected level of MMPs in tears during corneal wound healing.
The stromal keratocytes investigated in the present study
expressed MMP-2 and MMP-9 in response to corneal wounding,
with particularly strong expression of MMP-9 during phases of
epithelial cell migration and restratification. This was consistent
with findings following superficial keratectomy in rabbit corneas
[37]. It is possible that some MMPs detected in the tears from the
current study were produced by the stromal keratocytes located
within the vicinity of the wound bed. These MMPs may have
diffused through the anterior third of the stroma into the tear film
until the migrating epithelium had closed the wound. We believe
this contribution of the stromal keratocytes must have been
relatively small because procedural control eyes with the intact
epithelium showed similar MMP expressions as wounded eyes.
The immunoreactivity of the MMP-2 and MMP-9 in the
current study was significantly increased in the conjunctival
epithelium following wounding until the point of wound closure.
This elevation in MMP expression may be associated with an
increased number of inflammatory cells observed in the conjunctival stroma sub-adjacent to the conjunctival epithelium (data not
shown). Invading inflammatory cells may activate epithelial cells to
produce MMPs [38]. Comparison of MMP production patterns in
tears and conjunctival epithelial tissue did not however match
outcomes of the current study. The highest MMP activity in tears
in response to corneal wounding was detected during epithelial
migration, while in conjunctival tissue, the highest MMP
immunoreactivity was observed later, at the time of wound
PLOS ONE | www.plosone.org
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The inclusion of procedural control eyes showed that analgesic
and anesthetic medication, topical eye drops and use of eyelid
speculum or forceps to adjust the eyeball position during epithelial
wounding caused an increase in tear MMP activity. It is hard to
identify the individual contribution of each potential procedural
stimulant that resulted in increased MMP expression, as their
individual contributions were not tested and the outcome is likely
to be a combination of several of these factors. Furthermore, the
current study emphasizes the importance of using appropriate
experimental controls for the analysis of tears in wound healing
studies. Without using a procedural control, the analysis of tears in
this study would have led to the misconception that the migrating
corneal epithelium secreted most of MMP-2 and MMP-9 into
tears. Future studies that employ any sort of surgery or drug
treatment should also consider the use of the most appropriate
control taking these factors into account.
A feline model was used in the current study to investigate the
expression of MMPs in tears and the ocular surface system.
Previously, the feline cornea has been used as a model for the
human cornea in investigations of corneal wound healing [21–26],
corneal implants [45], and contact lens studies [46]. The feline
model, as with any other animal model, has some differences to
humans including the presence of nictitating membranes and the
general dimensions and size of the eye and surrounding organs.
Comparison of MMP-9 concentrations to those reported for
humans showed differences (slightly less MMP-9 in cats without
nictitating membranes and more in cats with membranes
compared to humans) [31]. These differences may be related to
the nature of the feline tear film, such as different lipid (meibum)
composition resulting in lower spontaneous eye blink rates, and
the presence of nictitating membranes which are rudimentary in
humans. Nevertheless, the feline model provided valuable insight
into the expression sites of MMP-2 and MMP-9 in response to
corneal epithelial wounding.

In summary, the major contributors to MMP-2 and MMP-9
found in feline tears in response to corneal wounding appear to be
the lacrimal gland and CALT. Other contributors to MMP
activity in tears are likely to be the corneal epithelium, stromal
keratocytes and conjunctival epithelium including goblet cells. The
meibomian glands do not appear to contribute at all to tearderived MMPs after corneal wounding.
This finding may have clinical importance for various ocular
surface conditions, including corneal wound healing and dry eye.
The inhibition of MMP-9 in tears has been shown to promote
healing and reduce inflammatory levels [47–49]. As the current
study exemplified, the lacrimal gland and CALT are major sources
for tear MMPs following wounding. It may therefore be more
effective to administer MMP inhibiting medication orally rather
than topically to target MMPs in these ocular surface tissues
[50,51].
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